<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851175</url>
  </required_header>
  <id_info>
    <org_study_id>rosucaff2</org_study_id>
    <nct_id>NCT00851175</nct_id>
  </id_info>
  <brief_title>Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?</brief_title>
  <official_title>Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Statins form a class of drugs that is widely prescribed for hypercholesterolaemia,
      specifically to reduce the risk on atherosclerosis by lowering LDL-cholesterol. Next to the
      effect for which the drug was originally developed, it became obvious that statins have
      several other beneficial effects. Such pleiotropic effects include the activation of
      ecto-5'-nucleotidase which can increase endogenous adenosine production (by dephosphorylation
      adenosine monophosphate into adenosine) and subsequently cause vasodilation. A recent study
      of Meijer et al (not yet published) showed that rosuvastatin significantly augments
      vasodilation after a brief period of ischemia (post occlusive reactive hyperaemia). However,
      it is not yet verified whether this increase in post occlusive reactive hyperaemia is truly
      caused by a rise of extracellular adenosine and subsequent adenosine receptor stimulation. In
      this study, the mechanism by which rosuvastatin augments post occlusive reactive hyperaemia
      will be investigated by blocking adenosine receptors with caffeine, a competitive A1 and A2
      adenosine receptor antagonist. Caffeine is a substance that can be safely used in normal
      concentrations to block the adenosine receptor.

      Hypothesis:

      The augmenting effect of rosuvastatin on PORH is caused by an increase of extracellular
      adenosine formation and this effect can be diminished by blocking the adenosine receptor
      using caffeine.

      Objective:

      To study the influence of caffeine on post occlusive reactive hyperaemia before and after 7
      days treatment with rosuvastatin.

      Study design:

      Open label cross-over design Study population: Healthy volunteers, 18-50 years of age

      Intervention:

      Eight volunteers will receive a 7 day treatment with rosuvastatin 20 mg daily before and
      after rosuvastatin treatment caffeine will be administrated intra-arterially.

      Main study parameters/endpoints:

      Forearm blood flow (FBF) will be measured as an indicator for post occlusive reactive
      hyperaemia (PORH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm blood flow (FBF)after 2, 5, and 13 minutes of forearm ischemia</measure>
    <time_frame>before and after 7 day treament with rosuvastatin, with and without concommitant intra-arterial treatment with caffeine</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>forearm bloodflow after 2,3, and 5 minutes of forearm ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>7 day treatment with rosuvastatin 1dd 20mg</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50

          -  Written informed consent

        Exclusion Criteria:

          -  History of any cardiovascular disease

          -  Hypertension (in supine position: systole &gt;140 mmHg, diastole &gt;90 mmHg)

          -  Diabetes Mellitus (fasting glucose &gt;7.0 mmol/L or random glucose &gt;11.0 mmol/L)

          -  Hyperlipidemia (fasting total cholesterol &gt;5.5 mmol/L or random cholesterol &gt;6.5
             mmol/L)

          -  Alanine amino transferase &gt;90 U/L

          -  Creatin kinase &gt;440 U/L

          -  Raised rhabdomyolysis risk (GFR &lt;80 ml/min and/or overt clinical signs of
             hypothyroidism and/or myopathy in family history

          -  Alcohol abuse

          -  Concommitant chronic use of medication

          -  Participation to any drug-investigation during the previous 60 days as checked with
             VIP check
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G Rongen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RUNMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Meijer P, Wouters CW, van den Broek PH, Scheffer GJ, Riksen NP, Smits P, Rongen GA. Dipyridamole enhances ischaemia-induced reactive hyperaemia by increased adenosine receptor stimulation. Br J Pharmacol. 2008 Mar;153(6):1169-76. doi: 10.1038/bjp.2008.10. Epub 2008 Feb 11.</citation>
    <PMID>18264130</PMID>
  </reference>
  <reference>
    <citation>Bijlstra PJ, den Arend JA, Lutterman JA, Russel FG, Thien T, Smits P. Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans. Diabetologia. 1996 Dec;39(12):1562-8.</citation>
    <PMID>8960843</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>G. Rongen MD PhD</name_title>
    <organization>RUNMC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

